- Bacterial meningitis
- Community acquired pneumonia
- Hospital acquired pneumonia
- Acute otitis media
- Intra-abdominal infections
- Complicated urinary tract infections (including pyelonephritis)
- Infections of bones and joints
- Complicated skin and soft tissue infections
- Gonorrhoea
- Syphilis
- Bacterial endocarditis
- Surgical prophylaxis
Adult: IM/IV 1000mg/125mg OD or divided doses BD *7-14 days
- Total daily dose should not exceed 4g of ceftriaxone
- Continue treatment for at least 2 days after the signs and symptoms have resolved
- Longer treatment may be needed in more serious infections.
- For Streptococci pyogenes infections, treatment should continue for at least 10 days.
Children: IM/IV 50-75 mg/kg/day given in divided doses BD *7-14 days for serious infections
- Expressed in terms of ceftriaxone
- Total daily dose should not exceed 2 g of ceftriaxone.
- Continue treatment for at least 2 days after the signs and symptoms have resolved. Longer treatment may be needed in more serious infections.
- For Streptococci pyogenes infections, treatment should continue for at least 10 days.
- Injection:
- 250mg/31.25mg
- Administered by deep IM, slow IV or as a slow IV infusion, after reconstitution with sterile water for injection
- IV injection should be administered over at least 24 minutes.
- IV infusion should be over a period of 30 minutes.
Ceftriaxone: 3rd generation cephalosporin with broad-spectrum gram-negative activity. Inhibits cell-wall synthesis by binding to 1 or more penicillin-binding proteins thus bactericidal.
Tazobactam: An irreversible inhibitor by covalently binding to β-lactamases, and prevents the enzyme hydrolysis of beta lactams
- Diarrhoea
- Rash
- Raised white blood cells
- Raised platelets
- Nausea
- Vomiting
- Upset stomach
- Blood clots
- Dizziness
- Headache
- A lump where the medicine was injected
- Sweating
- Hypersensitivity to drug/components
- Kidney or liver problems
- Diarrhea
- Hemolytic anemia
- Kidney or gall stones
- Inflammation of the large intestine
- In hyperbilirubinemic neonates/preterm newborns
- Probenecid
- Chloramphenicol
- Vancomycin
- Vitamin K antagonist
- Vecuronium
- Methotrexate
- Oral anticoagulants
- Heparin
- Alcohol (disulfiram-like reaction)
- Furosemide
Drug Status
| Availability | Prescription only |
| Pregnancy | Category B; use with caution |
| Breastfeeding | Where benefit outweighs risk |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Theotaz | 250mg/31.25mg | Injection | 1’s | Theon Pharma | Synermed Pharma |